Table 1 Binding capacity, neutralizing activity, and gene family analysis of 13 monoclonal Abs isolated from Patient #5, Patient #2, and Patient #22.

Patient	mAbs	Binding to RBD		Pseudovirus (μg/ml)		Live virus (μg/ml)		Heavy chain				Kappa chain (K) or Lambda chain (L)
Patient	mAbs	Kd (nM)	Competing w/ ACE2	IC₅₀	IC₈₀	IC₅₀	IC₈₀	IGHV	HCDR3	HCDR3 length	SHM (%)	IGK(L)V	K(L)CDR3	K(L)CDR3 length	SHM (%)
P#5	P5A-1B9	3.41	+++	0.0014	0.0053	0.0043	0.0441	4-59*01	ASNGQYYDILTGQPPDYWYFDL	22	0.70	K4-1*01	QQYYSTPLT	9	0.00
P#22	P22A-1D1	5.79	+++	0.0038	0.0625	0.0198	0.1321	3-53*01	ARDRDYYGMDV	11	0.00	K1-9*01	LHLNSYRT	8	0.38
P#5	P5A-2G7	3.95	+++	0.0044	0.0287	0.1814	0.8355	4-61*01	ARERCYYGSGRAPRCVWFDP	20	0.34	L2-14*01	SSYTSSSTLVV	11	0.74
P#5	P5A-1D1	6.83	+++	0.0096	0.0691	0.0189	0.0743	3-53*01	ARDLYYYGMDV	11	0.35	K1-9*01	QQLNSYPT	8	0.76
P#5	P5A-1B8	4.28	+++	0.0115	0.0501	0.0168	0.0857	3-53*01	ARETLAFDY	9	1.40	K1-9*01	QQLNSYPPA	9	0.00
P#5	P5A-2G9	15.94	+++	0.0158	0.1466	0.0113	0.1187	3–3301,3–3306	ARWFHTGGYFDY	12	0.00	L5-37*01	MIWPSNALYV	10	0.35
P#5	P5A-1D2	14.02	+++	0.0186	0.1025	0.0273	0.4325	3-53*01	ARALQVGATSDYFDY	15	1.40	L1-40*01	QSCDSSLSVVV	11	1.11
P#5	P5A-3C8	1.30	+++	0.0206	0.1031	0.0112	0.1499	3-53*01	ARDLQEHGMDV	11	1.05	K1-9*01	QHLNSYPPGYT	11	1.14
P#2	P2C-1F11*	3.64	+++	0.0286	0.1195	0.0323	0.1779	3-6601,3-6604	ARDLVVYGMDV	11	1.75	K3-20*01	QQYGSSPT	8	0.00
P#2	P2B-2F6*	5.57	+++	0.0500	0.6074	0.4074	2.4309	4-38-2*02	ARAVVGIVVVPAAGRRAFDI	20	0.69	L2-8*01	SSYAGSNNLV	10	0.00
P#2	P2B-1A10	38.41	+++	0.0974	0.7446	0.0639	0.3053	3-53*01	AREGPKSITGTAFDI	15	0.35	K1-3301,K1D-3301	QQYDNLPMYT	10	0.38
P#5	P5A-3B4	1.16	+	0.0993	1.0657	0.0561	1.0080	5-51*01	ARRDSTYGGNTDY	13	0.35	L1-44*01	AAWDDSLNGVV	11	0.00
P#5	P5A-3C12	8.47	+++	0.0996	0.4679	0.2636	2.6783	2–5*02	AHSLFLTVGYSSSWSPFDY	19	0.00	K4-1*01	QQYYSTPHT	9	0.00

The program IMGT/V-QUEST was applied to analyze gene germline, complementarity determining region (CDR) 3 length, and somatic hypermutation (SHM). The CDR3 length was calculated from amino acids sequences. The SHM frequency was calculated from the mutated nucleotides. Antibody binding to RBD was presented either by K_D or by competing with ACE2 where “+++” indicates >80% competition and “+” 20–50%. IC₅₀ represents the half-maximal whereas IC₈₀ the 80% inhibitory concentrations in the pseudovirus and live SARS-CoV-2 neutralization assay.
*Published in the reference (Ju, et al. ¹⁹).

Search